XML 24 R6.htm IDEA: XBRL DOCUMENT v3.22.1
Consolidated Statements of Cash Flows - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Cash flows from operating activities      
Net loss $ (13,070,251) $ (9,325,273)  
Adjustments to reconcile net loss to net cash used in operating activities:      
Stock-based compensation expense 1,784,102 1,651,893  
Amortization of held-to-maturity securities, net 329,612 331,277  
Unrealized gain from investment in Alphazyme 0 (284,709)  
Gain from the sale of investment in BDI (1,605,532) 0  
Foreign currency exchange loss 96,893 62,345  
Changes in operating assets and liabilities:      
Interest receivable 17,872 217,464  
Accounts receivable (31,792) 363,365  
Income tax receivable 0 500,616  
Prepaid expenses and other current assets (95,366) (2,410)  
Accounts payable 549,562 (53,200)  
Accrued expenses 219,824 (80,132)  
Deferred license revenue 500,000 0  
Deferred research and development obligations 28,131 44,372  
Net cash used in operating activities (11,276,945) (6,574,392)  
Cash flows from investing activities      
Purchases of held-to-maturity investment securities (11,283,940) (17,638,947)  
Proceeds from maturities of investment securities 14,900,000 39,761,000  
Proceeds from the sale of investment in BDI 1,605,532 0  
Net cash provided by investing activities 5,221,592 22,122,053  
Cash flows from financing activities      
Proceeds from exercise of options 1,230,050 255,470  
Net cash provided by financing activities 1,230,050 255,470  
Effect of exchange rate changes on cash (63,262) 10,370  
Net (decrease) increase in cash and cash equivalents (4,888,565) 15,813,501  
Cash and cash equivalents at beginning of period 20,637,045 4,823,544  
Cash and cash equivalents at end of period 15,748,480 20,637,045 $ 4,823,544
Supplemental cash flow information      
Cash received from income tax refund $ 0 $ 500,616 $ 500,000